Literature DB >> 26210126

Management of Systemic Sclerosis-Related Skin Disease: A Review of Existing and Experimental Therapeutic Approaches.

Elizabeth R Volkmann1, Daniel E Furst2.   

Abstract

The skin is the most common organ system involved in patients with systemic sclerosis (SSc). Nearly all patients experience cutaneous symptoms, including sclerosis, Raynaud's phenomenon, digital ulcers, telangiectasias, and calcinosis. In addition to posing functional challenges, cutaneous symptoms are often a major cause of pain, psychological distress, and body image dissatisfaction. The present article reviews the main features of SSc-related cutaneous manifestations and highlights an evidence-based treatment approach for treating each manifestation. This article also describes novel treatment approaches and opportunities for further research in managing this important clinical dimension of SSc.
Copyright © 2015 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cyclophosphamide (CYC); Diffuse cutaneous systemic sclerosis (DcSSc); Digital ulcers (DU); Hematopoietic stem cell transplantation (HSCT); Limited cutaneous systemic sclerosis (LcSSc); Methotrexate (MTX); Modified Rodnan skin score (mRSS); Raynaud’s phenomenon (RP)

Mesh:

Substances:

Year:  2015        PMID: 26210126     DOI: 10.1016/j.rdc.2015.04.004

Source DB:  PubMed          Journal:  Rheum Dis Clin North Am        ISSN: 0889-857X            Impact factor:   2.670


  8 in total

Review 1.  Assessment of skin involvement in systemic sclerosis.

Authors:  Gábor Kumánovics; Márta Péntek; Sangmee Bae; Daniela Opris; Dinesh Khanna; Daniel E Furst; László Czirják
Journal:  Rheumatology (Oxford)       Date:  2017-09-01       Impact factor: 7.580

2.  Integrated, multicohort analysis of systemic sclerosis identifies robust transcriptional signature of disease severity.

Authors:  Shane Lofgren; Monique Hinchcliff; Mary Carns; Tammara Wood; Kathleen Aren; Esperanza Arroyo; Peggie Cheung; Alex Kuo; Antonia Valenzuela; Anna Haemel; Paul J Wolters; Jessica Gordon; Robert Spiera; Shervin Assassi; Francesco Boin; Lorinda Chung; David Fiorentino; Paul J Utz; Michael L Whitfield; Purvesh Khatri
Journal:  JCI Insight       Date:  2016-12-22

3.  Treatment of Rapidly Progressive Systemic Sclerosis: Current and Futures Perspectives.

Authors:  Fabian A Mendoza; Maryah Mansoor; Sergio A Jimenez
Journal:  Expert Opin Orphan Drugs       Date:  2015-11-23       Impact factor: 0.694

4.  Stretching Reduces Skin Thickness and Improves Subcutaneous Tissue Mobility in a Murine Model of Systemic Sclerosis.

Authors:  Ying Xiong; Lisbeth Berrueta; Katia Urso; Sara Olenich; Igla Muskaj; Gary J Badger; Antonios Aliprantis; Robert Lafyatis; Helene M Langevin
Journal:  Front Immunol       Date:  2017-02-16       Impact factor: 7.561

Review 5.  Predicting the Progression of Very Early Systemic Sclerosis: Current Insights.

Authors:  Chiara Bellocchi; Augustine Chung; Elizabeth R Volkmann
Journal:  Open Access Rheumatol       Date:  2022-09-15

Review 6.  An update on the pharmacotherapeutic options and treatment strategies for systemic sclerosis.

Authors:  Zsuzsanna H McMahan; Elizabeth R Volkmann
Journal:  Expert Opin Pharmacother       Date:  2020-07-17       Impact factor: 3.889

7.  Natural History of Systemic Sclerosis-Related Interstitial Lung Disease: How to Identify a Progressive Fibrosing Phenotype.

Authors:  Elizabeth R Volkmann
Journal:  J Scleroderma Relat Disord       Date:  2019-12-05

8.  Scleroderma-related interstitial lung disease.

Authors:  Sally Suliman; Abdalhamid Al Harash; William Neil Roberts; Rafael L Perez; Jesse Roman
Journal:  Respir Med Case Rep       Date:  2017-07-15
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.